PRESS RELEASE published on 05/02/2025 at 01:50, 1 year ago BioNxt Solutions Announces Delay In Filing 2024 Annual Financial Statements BioNxt Solutions Inc. announces delay in filing annual financial statements for year ended December 31, 2024. Company working on completing filings by June 28, 2025, under management cease trade order Financial Statements Management Cease Trade Order BioNxt Solutions Inc. Delay Regulatory Authorities
BRIEF published on 04/23/2025 at 09:10, 1 year ago BioNxt Solutions Advances in MS Treatment Study Multiple Sclerosis Cladribine Drug Delivery Innovation BioNxt Solutions Bioequivalence Study
BRIEF published on 04/23/2025 at 09:10, 1 year ago BioNxt Solutions progresse dans une étude sur le traitement de la sclérose en plaques Sclérose En Plaques Cladribine Solutions BioNxt Étude De Bioéquivalence Innovation En Matière D'administration De Médicaments
PRESS RELEASE published on 04/23/2025 at 09:05, 1 year ago BioNxt Solutions Prepares for Human Bioequivalence Study For MS BioNxt Solutions Inc. reports advanced preparation for human bioequivalence study of BNT23001, a novel sublingual thin-film Cladribine formulation for Multiple Sclerosis treatment BioNxt Solutions Inc. Multiple Sclerosis Treatment Sublingual Thin-Film BNT23001 Human Bioequivalence Study
BRIEF published on 03/15/2025 at 00:05, 1 year 1 month ago BioNxt Solutions Closes Final Tranche of Convertible Debenture Offering Private Placement Convertible Debenture Warrants Financing BioNxt Solutions
BRIEF published on 03/15/2025 at 00:05, 1 year 1 month ago BioNxt Solutions clôture la dernière tranche de son offre d'obligations convertibles Financement Placement Privé Mandats Obligation Convertible Solutions BioNxt
PRESS RELEASE published on 03/15/2025 at 00:00, 1 year 1 month ago BioNxt Solutions Announces Closing of Final Tranche of Fully Subscribed Convertible Debenture Unit Private Placement BioNxt Solutions Inc. completes final tranche of convertible debenture Offering for $900,000. Funds to be used for product dev, IP, debt repayment, and working capital Private Placement Convertible Debenture Healthcare BioNxt Solutions Inc. Drug Delivery Technologies
BRIEF published on 03/01/2025 at 01:40, 1 year 2 months ago BioNxt Solutions Secures $1.6 Million in Convertible Debenture Private Placement Private Placement Convertible Debenture Investment BioNxt Solutions Proceeds Utilization
BRIEF published on 03/01/2025 at 01:40, 1 year 2 months ago BioNxt Solutions obtient 1,6 million de dollars en placement privé d'obligations convertibles Investissement Placement Privé Obligation Convertible Solutions BioNxt Utilisation Des Recettes
PRESS RELEASE published on 03/01/2025 at 01:35, 1 year 2 months ago BioNxt Solutions Announces Closing of First Tranche of Convertible Debenture Unit Private Placement BioNxt Solutions Inc. closes first tranche of convertible debenture units Offering, raising $1.6M. Proceeds for product development, IP filings, debt repayment, and working capital Private Placement BioNxt Solutions Inc. Intellectual Property Product Development Convertible Debenture Units
Published on 05/09/2026 at 01:30, 3 hours 38 minutes ago Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 5 hours 8 minutes ago Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 20:38, 8 hours 30 minutes ago EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 9 hours 55 minutes ago EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 10 hours 6 minutes ago Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/07/2026 at 19:15, 1 day 9 hours ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 1 day 9 hours ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 1 day 10 hours ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 1 day 10 hours ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 1 day 10 hours ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
